News

Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved the PD-1 inhibitor Libtayo (cemiplimab-rwlc) in combination with platinum-based…
Read More...

NRG Therapeutics, Ltd., an innovative neuroscience company targeting mitochondrial dysfunction, announced the closing of a £16 million Series A financing, led by Omega Funds and joined…
Read More...

Royalty Pharma plc and Arrowhead announced that Royalty Pharma has acquired a royalty interest in Amgen’s olpasiran from Arrowhead Pharmaceuticals for $250 million in cash upfront plus…
Read More...

A wholly-owned subsidiary of Sun Pharmaceutical Industries Limited and Sun Pharma Advanced Research Company Ltd. announced the signing of a licensing agreement for commercialization of…
Read More...

ProPhase Labs, Inc. announced that its wholly owned subsidiary, ProPhase BioPharma, Inc. (“PBIO”), and Dana-Farber Cancer Institute have entered into a two-year collaborative agreement…
Read More...

Following European Commission approval earlier this month, the Medicines and Healthcare products Regulatory Agency (MHRA) has approved Beyfortus (nirsevimab) for the prevention of…
Read More...

Immunomic Therapeutics, Inc. (ITI), a privately-held clinical-stage biotechnology company pioneering the development of LAMP-mediated nucleic acid-based immunotherapy, announced that…
Read More...

Bruker Corporation announced the acquisition of Inscopix, Inc., a neuroscience pioneer and market leader of miniaturized microscopes, known as miniscopes, for freely moving animal brain…
Read More...

Spero Therapeutics, Inc., a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving…
Read More...

Swedish biotech company Salipro Biotech AB announced that it has entered into a research collaboration and license agreement with Sanofi on the discovery of therapeutic biologics…
Read More...

Navrogen, Inc. announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with researchers at the U.S. National Cancer Institute (NCI), part of the…
Read More...

Mauna Kea Technologies inventor of Cellvizio, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, and Tasly Pharmaceutical Group announced the…
Read More...

Fulgent Genetics, Inc. a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, announced that…
Read More...

Cyagen announced a strategic collaboration with Neurophth Therapeutics, Inc. to co-develop next-generation AAV gene therapy vectors for specific types of genetic ophthalmic disorders.…
Read More...

Amgen presented end-of-treatment data from its Phase 2 OCEAN(a)-DOSE study of investigational olpasiran (formerly AMG 890) in adults with elevated lipoprotein(a) levels (>150…
Read More...

Asieris Pharmaceuticals, a global biopharmaceutical company specializing in the discovery and development of innovative drugs for the treatment of genitourinary tumors and other major…
Read More...

Reaction Biology Corporation (“Reaction”), an industry-leading provider of drug discovery services, and Vyant Bio, Inc. (“Vyant Bio”), an innovative biotechnology company reinventing…
Read More...

The European Commission has approved Beyfortus (nirsevimab) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants during their…
Read More...

NKGen Biotech, Inc., a biotechnology company harnessing the power of the body’s immune system through the development of natural killer (NK) cell therapies, announced a collaboration…
Read More...

BeiGene announced that the European Commission (EC) has granted marketing authorization of BRUKINSA (zanubrutinib) for the treatment of adult patients with relapsed/refractory (R/R)…
Read More...